within Pharmacolibrary.Drugs.R_RespiratorySystem.R01A_DecongestantsAndOtherNasalPreparationsForTopical.R01AD08_Fluticasone;

model Fluticasone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.8333333333333333e-05,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.318,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fluticasone</td></tr><tr><td>ATC code:</td><td>R01AD08</td></tr><td>route:</td><td>intranasal</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>318</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.1</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fluticasone is a synthetic corticosteroid with potent anti-inflammatory properties. It is commonly used as a nasal spray for the treatment of allergic rhinitis and as an inhaled medication for asthma and chronic obstructive pulmonary disease (COPD). Fluticasone is approved and widely used today in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following intranasal administration of fluticasone propionate.</p><h4>References</h4><ol><li><p>Wolthers, OD (2013). New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. <i>Recent patents on inflammation &amp; allergy drug discovery</i> 7(3) 223–228. DOI:<a href=\"https://doi.org/10.2174/1872213x113079990019\">10.2174/1872213x113079990019</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23862774/\">https://pubmed.ncbi.nlm.nih.gov/23862774</a></p></li><li><p>Wang, P, et al., &amp; Li, X (2025). Pharmacokinetics and Bioequivalence of 2 Products of Fluticasone Propionate Nasal Spray in Healthy Chinese Subjects. <i>Clinical pharmacology in drug development</i> 14(5) 398–403. DOI:<a href=\"https://doi.org/10.1002/cpdd.1507\">10.1002/cpdd.1507</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39828962/\">https://pubmed.ncbi.nlm.nih.gov/39828962</a></p></li><li><p>Chen, G, et al., &amp; Wang, J (2025). Bioequivalence Study of 2 Formulations of Fluticasone Nasal Spray in Healthy Chinese Volunteers. <i>Clinical pharmacology in drug development</i> 14(3) 270–275. DOI:<a href=\"https://doi.org/10.1002/cpdd.1505\">10.1002/cpdd.1505</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39789740/\">https://pubmed.ncbi.nlm.nih.gov/39789740</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R01AD08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fluticasone;
